ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage immuno-oncology biotechnology company founded in 2017 and headquartered in South San Francisco, California. The company went public in October 2018 and has positioned itself as a pioneer in developing "off-the-shelf" allogeneic CAR T cell therapies for cancer treatment and autoimmune diseases. Unlike traditional CAR T therapies that require extracting and modifying a patient's own immune cells, Allogene's approach uses genetically engineered T cells from healthy donors that can be manufactured in advance and stored for immediate use when needed.